Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha, Hunan, 410011, China; Institute of Clinical Pharmacy, Central South University, Changsha, Hunan, 410011, China.
School of Pharmacy, Hunan University of Chinese Medicine, Changsha, Hunan, 410208, China.
Comput Biol Med. 2022 Dec;151(Pt A):106298. doi: 10.1016/j.compbiomed.2022.106298. Epub 2022 Nov 11.
Recently, it has been reported that cepharanthine (CEP) is highly likely to be an agent against Coronavirus disease 2019 (COVID-19). In the present study, a network pharmacology-based approach combined with RNA-sequencing (RNA-seq), molecular docking, and molecular dynamics (MD) simulation was performed to determine hub targets and potential pharmacological mechanism of CEP against COVID-19.
Targets of CEP were retrieved from public databases. COVID-19-related targets were acquired from databases and RNA-seq datasets GSE157103 and GSE155249. The potential targets of CEP and COVID-19 were then validated by GSE158050. Hub targets and signaling pathways were acquired through bioinformatics analysis, including protein-protein interaction (PPI) network analysis and enrichment analysis. Subsequently, molecular docking was carried out to predict the combination of CEP with hub targets. Lastly, MD simulation was conducted to further verify the findings.
A total of 700 proteins were identified as CEP-COVID-19-related targets. After the validation by GSE158050, 97 validated targets were retained. Enrichment results indicated that CEP acts on COVID-19 through multiple pathways, multiple targets, and overall cooperation. Specifically, PI3K-Akt signaling pathway is the most important pathway. Based on PPI network analysis, 9 central hub genes were obtained (ACE2, STAT1, SRC, PIK3R1, HIF1A, ESR1, ERBB2, CDC42, and BCL2L1). Molecular docking suggested that the combination between CEP and 9 central hub genes is extremely strong. Noteworthy, ACE2, considered the most important gene in CEP against COVID-19, binds to CEP most stably, which was further validated by MD simulation.
Our study comprehensively illustrated the potential targets and underlying molecular mechanism of CEP against COVID-19, which further provided the theoretical basis for exploring the potential protective mechanism of CEP against COVID-19.
最近有报道称,石蒜碱(CEP)极有可能成为对抗 2019 年冠状病毒病(COVID-19)的药物。本研究采用网络药理学方法结合 RNA 测序(RNA-seq)、分子对接和分子动力学(MD)模拟,确定 CEP 对抗 COVID-19 的关键靶点和潜在药理机制。
从公共数据库中检索 CEP 的靶点。从数据库和 RNA-seq 数据集 GSE157103 和 GSE155249 中获取 COVID-19 相关靶点。然后通过 GSE158050 验证 CEP 和 COVID-19 的潜在靶点。通过生物信息学分析,包括蛋白质-蛋白质相互作用(PPI)网络分析和富集分析,获取关键靶点和信号通路。随后,进行分子对接以预测 CEP 与关键靶点的结合。最后,进行 MD 模拟以进一步验证发现。
共鉴定出 700 种蛋白质为 CEP-COVID-19 相关靶点。经 GSE158050 验证后,保留了 97 个验证靶点。富集结果表明,CEP 通过多种途径、多个靶点和整体协同作用作用于 COVID-19。具体而言,PI3K-Akt 信号通路是最重要的通路。基于 PPI 网络分析,获得了 9 个核心关键基因(ACE2、STAT1、SRC、PIK3R1、HIF1A、ESR1、ERBB2、CDC42 和 BCL2L1)。分子对接表明 CEP 与 9 个核心关键基因的结合极为牢固。值得注意的是,ACE2 被认为是 CEP 对抗 COVID-19 最重要的基因,与 CEP 的结合最稳定,这通过 MD 模拟进一步得到了验证。
本研究全面阐述了 CEP 对抗 COVID-19 的潜在靶点和潜在分子机制,为进一步探索 CEP 对抗 COVID-19 的潜在保护机制提供了理论依据。